2023 2022 2021 2020 2019 Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update Mar 23, 2023 Read More » Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023 Mar 21, 2023 Read More » Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results Mar 16, 2023 Read More » Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD Mar 15, 2023 Read More » Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference Mar 07, 2023 Read More » Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease Feb 22, 2023 Read More » Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia Feb 21, 2023 Read More » Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease Feb 09, 2023 Read More »
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update Mar 23, 2023 Read More »
Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023 Mar 21, 2023 Read More »
Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD Mar 15, 2023 Read More »
Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference Mar 07, 2023 Read More »
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease Feb 22, 2023 Read More »
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia Feb 21, 2023 Read More »
Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease Feb 09, 2023 Read More »
